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Recent evidence highlights an increase in ‘chemsex’, the use of recreational drugs during 27 
sex, in men who have sex with men (MSM) and an association with risky sexual behaviours 28 
and outbreaks of sexually transmitted infections (STIs). 1 However, the extent of sexualised 29 
drug use in people attending sexual health clinics (SHCs) is unknown.  30 
STI surveillance in England is performed by Public Health England (PHE) using a 31 
disaggregated patient-level dataset of all diagnoses and services at SHCs. 2 This is a 32 
minimum dataset with key demographic and clinical variables, but lacks behavioural data. To 33 
address this gap, PHE piloted a surveillance enhancement to collect behavioural data, 34 
including sexualised drug use (an affirmative response to ‘were you under the influence of 35 
recreational drugs [before or during sex] with any partner in the last 3 months?’). A pilot in 36 
six SHCs throughout England took place from August 2013 to April 2014; at each clinic, 37 
attendees’ behavioural data were collected for all new patient episodes. 38 
Complete data on 8,741 attendances were submitted (48.5% of eligible attendances). 39 
Overall, the proportion where sexualised drug use was reported was 6.6%, ranging from 40 
4.1% in heterosexual women to 12.1% in MSM. Among the 519 MSM who reported at least 41 
one sex partner in the last three months, the most commonly reported drugs used before/ 42 
during sex were mephedrone (10.4%), -hydroxybutyrate/-butyrolactone (GHB/GBL, 7.1%) 43 
and cannabis (6.7%). Chemsex is usually associated with mephedrone, crystal 44 
methamphetamine or GHB/GBL 1 and, among MSM who reported using them before/during 45 
sex, the proportion who injected ranged from 7.4% (4/54, mephedrone) to 42.1% (8/19, 46 
crystal methamphetamine). 47 
These preliminary data suggest that sexualised drug use is commonly reported by SHC 48 
attendees, especially MSM, and highlight the utility of monitoring drug use at SHCs to 49 
identify local needs and plan care pathways for appropriate treatment services. 50 
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